GIMV invests in Belgian biotech company Actogenix
GIMV, Biotech Fund Flanders and Life Sciences Partners together invest EUR 11.5 million in the Series-A funding round of ActoGenix, a Belgian biotech start-up and spin-off from the Flanders Interuniversity Institute for Biotechnology (VIB). GIMV and Life Sciences Partners act as co-lead investors.
ActoGenix is the 5th venture-capital backed spin-off of the Flanders interuniversity Institute for Biotechnology (VIB) after Devgen, CropDesign, Ablynx and Peakadilly. The company was started in June 2006 with seed capital from GIMV, VIB and the management team.
ActoGenix will use the proceeds of this financing to initiate development of a pipeline of therapeutic products based on its TopAct™ technology platform. TopAct™ is a proprietary delivery system comprising living micro-organisms for the oral administration of biopharmaceuticals. ActoGeniX’ products will address a broad range of diseases, including gastrointestinal diseases, auto-immunity, allergy and metabolic disease. The company’s lead product for the treatment of Crohn’s disease has already been successfully tested in patients.
More information on ActoGenix can be found in the attached press release of the company.
For more information, please contact: - Mr. Frank De Leenheer – Investor Relations Manager GIMV
Tel: +32 3 290 22 18 - E-mail: firstname.lastname@example.org
- Mr. Patrick Van Beneden – Executive Vice President GIMV
Tel: +32 3 290 21 58 – E-mail: email@example.com
Annex: Press release ActoGenix